PaxMedica, Inc. Common Stock (PXMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -18.28 Million USD | -23.56% |
| 2022 | -14.8 Million USD | -13.56% |
| 2021 | -13.03 Million USD | -53.55% |
| 2020 | -8.48 Million USD | -1318.12% |
| 2019 | -598.6 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.69 Million USD | 37.62% |
| 2024 Q2 | -2.99 Million USD | 18.83% |
| 2023 Q2 | -3.48 Million USD | 4.08% |
| 2023 FY | -18.28 Million USD | 3.71% |
| 2023 Q1 | -3.63 Million USD | 33.43% |
| 2023 Q3 | -5.04 Million USD | -44.83% |
| 2023 Q4 | -5.92 Million USD | -17.26% |
| 2022 Q4 | -5.45 Million USD | 73.01% |
| 2022 Q3 | -20.23 Million USD | -2195.49% |
| 2022 Q2 | 965.45 Thousand USD | -83.16% |
| 2022 Q1 | 5.73 Million USD | -8.05% |
| 2022 FY | -18.99 Million USD | -45.72% |
| 2021 Q2 | -6.13 Million USD | 15.08% |
| 2021 Q1 | -7.22 Million USD | -64.81% |
| 2021 FY | -13.03 Million USD | -53.55% |
| 2021 Q4 | 6.23 Million USD | 300.38% |
| 2021 Q3 | -3.11 Million USD | 49.27% |
| 2020 Q4 | -4.38 Million USD | -166.64% |
| 2020 Q3 | -1.64 Million USD | -7.6% |
| 2020 Q2 | -1.52 Million USD | -454.8% |
| 2020 FY | -8.48 Million USD | -1318.12% |
| 2020 Q1 | -275.22 Thousand USD | 0.0% |
| 2019 Q1 | -114.37 Thousand USD | 0.0% |
| 2019 Q2 | -137.89 Thousand USD | -20.56% |
| 2019 FY | -598.6 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -2302.055% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -111.883% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 40.519% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 85.264% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -13.756% |
| Better Therapeutics, Inc. | -39.76 Million USD | 54.0% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 3.055% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 0.48% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 48.927% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 49.287% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 84.03% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -713.506% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 75.533% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 69.043% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -205.426% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 14.109% |
| Molecular Templates, Inc. | -8.12 Million USD | -125.132% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -20.508% |
| NexImmune, Inc. | -32.34 Million USD | 43.453% |
| Orgenesis Inc. | -55.36 Million USD | 66.963% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 27.603% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -23343.256% |
| Scopus BioPharma Inc. | -11.6 Million USD | -57.537% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 96.807% |
| Statera Biopharma, Inc. | -174.4 Million USD | 89.513% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -409.747% |
| Trevena, Inc. | -40.28 Million USD | 54.604% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -32024.434% |
| Vaccinex, Inc. | -20.25 Million USD | 9.685% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -1447.207% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 64.179% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -135.172% |